Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulbactam is a small molecule beta-lactamase inhibitor used primarily in combination with beta-lactam antibiotics to treat a variety of bacterial infections. It works by irreversibly inhibiting bacterial beta-lactamase enzymes, which are responsible for hydrolyzing and inactivating many penicillin and cephalosporin antibiotics. By blocking these enzymes, sulbactam restores or enhances the activity of partner antibiotics against beta-lactamase-producing bacteria. Sulbactam itself has weak intrinsic antibacterial activity but can inhibit penicillin-binding proteins (PBP1 and PBP3), particularly in certain species such as Acinetobacter baumannii. It is commonly combined with ampicillin (Unasyn), cefoperazone (Sulperazon), or durlobactam (Xacduro) for clinical use[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulbactam.